180 Wealth Advisors LLC Cuts Stock Position in Bristol-Myers Squibb (NYSE:BMY)

180 Wealth Advisors LLC lessened its position in Bristol-Myers Squibb (NYSE:BMY) by 1.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 19,109 shares of the biopharmaceutical company’s stock after selling 289 shares during the quarter. 180 Wealth Advisors LLC’s holdings in Bristol-Myers Squibb were worth $1,231,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. True Wealth Design LLC purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at $26,000. GoalVest Advisory LLC purchased a new stake in shares of Bristol-Myers Squibb in the 1st quarter valued at $29,000. Coppell Advisory Solutions Corp. purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at $31,000. Live Oak Investment Partners purchased a new stake in Bristol-Myers Squibb during the 4th quarter worth about $33,000. Finally, Strengthening Families & Communities LLC increased its holdings in Bristol-Myers Squibb by 90.0% during the 1st quarter. Strengthening Families & Communities LLC now owns 475 shares of the biopharmaceutical company’s stock worth $656,000 after purchasing an additional 225 shares during the period. Hedge funds and other institutional investors own 74.98% of the company’s stock.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Ann Powell sold 17,986 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of $61.25, for a total transaction of $1,101,642.50. Following the completion of the sale, the executive vice president now directly owns 27,868 shares of the company’s stock, valued at approximately $1,706,915. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, EVP Robert M. Plenge sold 732 shares of the stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $61.14, for a total transaction of $44,754.48. Following the completion of the transaction, the executive vice president now directly owns 6,584 shares of the company’s stock, valued at approximately $402,545.76. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Ann Powell sold 17,986 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $61.25, for a total value of $1,101,642.50. Following the completion of the transaction, the executive vice president now directly owns 27,868 shares of the company’s stock, valued at $1,706,915. The disclosure for this sale can be found here. 0.09% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on BMY shares. BMO Capital Markets cut their price target on Bristol-Myers Squibb from $87.00 to $79.00 and set an “outperform” rating on the stock in a report on Friday, July 28th. TD Cowen cut their price target on Bristol-Myers Squibb from $80.00 to $66.00 and set a “market perform” rating on the stock in a report on Friday. Morgan Stanley restated an “underweight” rating and set a $59.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, July 19th. Daiwa Capital Markets began coverage on Bristol-Myers Squibb in a report on Wednesday, June 28th. They set an “outperform” rating and a $70.00 price target on the stock. Finally, HSBC began coverage on Bristol-Myers Squibb in a research report on Friday, July 14th. They set a “reduce” rating and a $56.00 price objective for the company. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average price target of $70.67.

Bristol-Myers Squibb Stock Performance

Shares of NYSE BMY traded down $0.38 during trading hours on Monday, reaching $58.65. The stock had a trading volume of 2,067,508 shares, compared to its average volume of 8,917,258. The firm has a 50-day moving average of $61.62 and a 200-day moving average of $65.11. The company has a current ratio of 1.39, a quick ratio of 1.28 and a debt-to-equity ratio of 1.08. The firm has a market cap of $122.53 billion, a price-to-earnings ratio of 15.70, a PEG ratio of 1.58 and a beta of 0.42. Bristol-Myers Squibb has a fifty-two week low of $58.33 and a fifty-two week high of $81.43.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.75 EPS for the quarter, missing the consensus estimate of $1.99 by ($0.24). The company had revenue of $11.23 billion for the quarter, compared to analysts’ expectations of $11.81 billion. Bristol-Myers Squibb had a net margin of 17.62% and a return on equity of 50.51%. The firm’s revenue was down 5.6% on a year-over-year basis. During the same period in the prior year, the company earned $1.93 earnings per share. Equities research analysts predict that Bristol-Myers Squibb will post 7.49 earnings per share for the current year.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.